Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Oxlumo Market Revenue Growth Supported By A CAGR Of % Through 2030
The historic expansion was driven by better genetic screening for primary hyperoxaluria, a shortage of earlier treatment options, progress in RNA-based therapeutics, greater recognition of uncommon kidney diseases, and orphan drug regulatory approvals.
The expansion of gene-silencing therapeutic pipelines, increased investment in rare disease drug development, greater adoption of precision nephrology treatments, improved global access to genetic diagnostics, and enhanced long-term disease management strategies are driving growth in the forecast period. Key trends shaping this period include the growing uptake of RNA interference therapies, a heightened emphasis on genetic kidney disorders, the broadening of precision medicine for rare diseases, the rising utilization of subcutaneous targeted therapies, and more advanced monitoring of metabolic disease progression.
Download A Free Sample Report For Comprehensive Market Insights:
Oxlumo Market Development Factors: Which Trends Are Supporting Demand?
The growing emphasis on personalized medicine is anticipated to drive expansion in the oxlumo market in the coming period. Personalized medicine is a healthcare strategy that customizes treatment plans and therapies according to an individual’s genetic profile, lifestyle, and environmental influences to optimize therapeutic results. This heightened focus on personalized medicine stems from progress in genomics, which enables more precise and effective interventions tailored to a person’s genetic and lifestyle characteristics. Oxlumo (lumasiran) supports personalized medicine by addressing specific genetic mutations in patients with primary hyperoxaluria type 1 (PH1), a rare hereditary condition, providing a customized approach to lower oxalate production and avert kidney injury based on a patient’s genetic makeup. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based organization, reported that in 2023, the FDA approved 16 new personalized therapies for individuals with rare diseases, up from six in 2022. Consequently, the rising focus on personalized medicine is fueling growth in the oxlumo market.
The rising incidence of primary hyperoxaluria is projected to accelerate the expansion of the oxlumo market in the future. Primary hyperoxaluria is a rare genetic condition marked by excessive oxalate production, which can result in kidney stone formation, renal impairment, and other health issues. The occurrence of primary hyperoxaluria is linked to genetic defects that hinder the body’s capacity to process oxalate, causing its buildup and potential kidney harm. Oxlumo helps manage primary hyperoxaluria by blocking the enzyme alanine-glyoxylate aminotransferase (AGT), thereby reducing oxalate generation and lowering the likelihood of kidney damage. As an illustration, in October 2024, Kidney Care UK, a UK-based nonprofit, noted that hyperoxaluria impacts roughly 1 in 500,000 people in the UK. Type 1 is the predominant variant, representing 80% of cases, while Types 2 and 3 each account for about 10%. Additionally, in October 2023, the National Center for Biotechnology Information, a US national library of medicine, indicated that European epidemiological data estimates PH1 prevalence at 1 to 3 cases per million. Thus, the growing prevalence of primary hyperoxaluria is propelling the oxlumo market forward.
Oxlumo Market Segments: Where Are The Largest Growth Opportunities?
The oxlumo market covered in this report is segmented –
1) By Clinical Indication: Primary Hyperoxaluria Type 1 (PH1), Kidney Stones, End-Stage Renal Disease (ESRD)
2) By Distribution Channel: Retail Pharmacies, Online Pharmacies
3) By End User: Pediatric, Adult
Oxlumo Market Transformation Trends: Which Innovations Are Driving Change?
In the Oxlumo market, major industry players are dedicating their efforts to in vivo gene-editing therapies, particularly single-dose CRISPR-based treatments aimed at inactivating the HAO1 gene. This gene is responsible for encoding glycolate oxidase, and its disruption in the liver can effectively decrease oxalate production. To clarify, an in vivo gene-editing therapy involves the direct delivery of a gene editor—such as a CRISPR/Cas nuclease—into a patient’s hepatocytes, often using lipid nanoparticles (LNPs) to modify the target gene within the body, with the potential for a long-lasting or even one-time cure. As an example, in August 2024, YolTech Therapeutics, a gene-editing company based in China, administered the first dose of YOLT-203 to a patient; this is an in vivo gene-editing therapy intended for primary hyperoxaluria type 1 (PH1). YOLT-203 relies on YolTech’s proprietary YolCas12 editor, delivered via an LNP-mRNA system, and specifically targets the HAO1 gene within hepatocytes. Notable characteristics of YOLT-203 include its single-dose, potentially curative approach, the utilization of YolTech’s HEPDONE-evolved Cas12 editor for high-precision and efficient editing, as well as targeted delivery through a lipid nanoparticle formulation that ensures liver-specific uptake.
Oxlumo Market Major Participants And Competitive Dynamics
Major companies operating in the oxlumo market are Alnylam Pharmaceuticals Inc.
Access The Complete Oxlumo Market Report:
Oxlumo Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the oxlumo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oxlumo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model